#Cost of Poor Quality (COPQ)
Browse all posts tagged with Cost of Poor Quality (COPQ)
Deviation Backlogs Are Not Linear: Understanding the Hidden Factory in GMP Investigations
April 1, 2026 • By Mike Barlow
Deviation investigations are often managed as a linear workload—one record, one investigation, one unit of effort. This assumption holds only while the system operates within capacity. Once backlog forms, the system behavior changes. Effort no longer scales with the number of deviations; it expands nonlinearly as coordination, prioritization, and aging effects take over. The result is a Hidden Factory—capacity consumed not by resolving deviations, but by managing them. Understanding this shift is critical: restoring performance is not about working harder, but about re-establishing flow in a system that has crossed into exponential cost.
Don’t Start Conversations as a Bulldozer — Start Them as a Domino
March 25, 2026 • By Paul Van Buskirk
Most operational conversations in pharmaceutical manufacturing begin like bulldozers—forceful, reactive, and loud. Effective leaders start them like dominos: small, precise actions that trigger system-wide improvement.
GMPWit™ Whitepaper | Structured Productivity in GMP Environments
March 19, 2026 • By Paul Van Buskirk, Mike Barlow
GMPWit™ introduces structured productivity to GMP environments, improving how deviation investigations, CAPAs, and operational work are created—without impacting validated systems or regulatory compliance.
Exposing the Hidden Factory: How COPQ Reveals Capacity Constraints
March 18, 2026 • By Mike Barlow
The Hidden Factory represents unmeasured capacity consumed by internal failure activities such as deviation investigations, production rework, and documentation errors. While these activities are tracked operationally, their economic impact is rarely quantified. Applying the Cost of Quality framework translates this consumption into financial terms, providing a basis for capacity recovery and risk-informed prioritization aligned with ICH Q9 and Q10.
What Is the Cost of Poor Quality in Pharmaceutical Manufacturing?
March 10, 2026 • By Paul Van Buskirk
Cost of Poor Quality (COPQ) represents the hidden financial losses created when pharmaceutical manufacturing systems fail to execute consistently. While many sites track deviations, investigations, and batch failures, few translate those operational issues into financial impact. In many pharmaceutical organizations, COPQ quietly represents 25–40% of operational cost. Understanding where those losses originate is the first step toward restoring execution stability and recovering lost manufacturing capacity.
Dashboards Don’t Stop Debris
February 26, 2026 • By Paul Van Buskirk
Dashboards were never meant to be decorative. The original dashboard existed to stop debris before it reached the passenger. Modern business dashboards do the opposite — they measure the mess after it hits. In pharmaceutical manufacturing, that mess shows up as lost batches, deviation backlog, delayed disposition, and rework — the true drivers of Cost of Poor Quality. Visibility alone does not prevent failure. Structural correction does.
How to Calculate Your Facility's True COPQ (Free Calculator)
July 24, 2025 • By Mike Barlow, Paul Van Buskirk
Cost of Poor Quality (COPQ) can quietly erode margins in biopharma operations through rework, deviations, delays, and batch losses. This post breaks down the four key components of quality cost—prevention, appraisal, internal failure, and external failure—and introduces a free COPQ calculator to help you estimate the true financial impact and identify opportunities for ROI.
What is a GMP Deviation Investigation?
August 26, 2023 • By Mike Barlow
In GMP pharmaceutical production, including biologics and cell therapy manufacturing, a GMP Deviation Investigation is the structured process used to identify, document, analyze, and resolve any unexpected events or conditions that do not comply with approved procedures, specifications, or regulatory requirements.